Join
Live feed
·
PRReleasevia Quantisnow
Creative Medical Technology Holdings Inc. logo

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

ByQuantisnow·Wall Street's wire, on your screen.
CELZ· Creative Medical Technology Holdings Inc.
Finance

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CELZ (Creative Medical Technology Holdings Inc.) and more on Quantisnow.